Cardiomyocytes Market Analysis

Type (Human iPSC-Derived Cardiomyocytes, Rat Cardiomyocytes)

The human iPSC-derived cardiomyocytes segment is predicted to account for 60% share of the cardiomyocytes market by 2036. The segment growth can be attributed to the rising prevalence of cardiovascular diseases, such as coronary heart disease, stroke, hypertension, and congestive heart failure. According to the data published by the World Health Organization cardiovascular diseases (CVDs) are the leading cause of death globally, taking an estimated 17.9 million lives each year. Cardiomyocytes produced from induced pluripotent stem cells (iPSC) can improve the precision, efficacy, and accuracy of identifying cardiovascular damage hazards in drugs as well as non-pharmaceutical methods. Hence, increasing the demand for human iPSC-derived cardiomyocytes in the cardiomyocytes market.

Application (Independent assays, Cardiac Disease Modeling, Cardiac safety & Toxicity)

Cardiac safety and toxicity segmented in cardiomyocytes market is estimated to gain a significant share during the forecast period. The segment growth can be attributed to the global rise in cardiotoxicity brought on by an increased prevalence of cancer. Cardiotoxicity is the term for heart damage caused by several cancer medications or treatments and results in cardiac diseases including but not limited to arrhythmia, myocardial infarction, and myocardial hypertrophy. Research by the World Cancer Research Fund Internation shows that there were an estimated 18.1 million cancer cases around the world in 2020. Thus showing significant growth in the cardiomyocyte market in the forecast period.

Our in-depth analysis of the Cardiomyocytes market includes the following segments:

Type	Human iPSC-derived Cardiomyocytes Rat Cardiomyocytes
Application	Independent assays Cardiac Disease Modeling Cardiac safety & Toxicity
End-Users	Private Research Laboratory Academic Research Institute Drug Manufacturers

Frequently Asked Questions (FAQ)

The major factors driving the growth of the Cardiomyocytes market are the rising incidence of cardiovascular diseases in the world, rising investments in research and development, expanding adoption of cell therapy, and increase in healthcare expenditure and reimbursement policies.

The market size of cardiomyocytes is anticipated to attain a CAGR of 10% over the forecast period, i.e., 2024-2036.

The major players in the market are AstraZeneca, Novartis, Pfizer, Roche, Johnson & Johnson, Merck & Co., Inc., Bayer, Abbott Laboratories, Bristol Myres, Cytiva, and others.

The Human iPSC-derived Cardiomyocytes segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North America region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.

Cardiomyocytes Market Analysis